Cagrilintide

Cagrilintide is Novo Nordisk's bet on combination obesity pharmacotherapy and the molecule that anchors the most-watched late-stage weight-management program of 2025–2026. It is one of two amylin analogs to reach clinical development: pramlintide (Symlin) has been FDA-approved since 2005 as an adjunct to mealtime insulin in type 1 and type 2 diabetes (Ryan et al., Clin Ther 2005, 27(10):1500–1512), but its three-times-daily dosing and modest weight effect kept it from displacing any incumbent obesity therapy. Cagrilintide's case for clinical relevance rests on once-weekly dosing and on co-formulation with semaglutide — not on monotherapy performance.

The monotherapy data are honest but unspectacular. The Phase 1b safety and pharmacokinetic study established the once-weekly profile: Enebo et al., Lancet 2021, 397(10286):1736–1748 randomized 96 adults with BMI 27.0–39.9 kg/m² to escalating doses of cagrilintide (0.16–4.5 mg) co-administered with semaglutide 2.4 mg or to placebo across a 20-week regimen. The cagrilintide half-life was 159–195 hours, the semaglutide half-life 145–165 hours, and the two molecules showed no clinically meaningful pharmacokinetic interaction. Weight loss at week 20 across the active arms was 15.4–17.1%, all on top of semaglutide 2.4 mg — the first signal that the combination might exceed semaglutide monotherapy. The Phase 2 dose-finding monotherapy trial then established cagrilintide-alone performance directly: Lau et al., Lancet 2021, 398(10317):2160–2172 randomized 706 adults with overweight or obesity at 57 sites across ten countries to subcutaneous once-weekly cagrilintide (0.3, 0.6, 1.2, 2.4, or 4.5 mg), once-daily liraglutide 3.0 mg, or volume-matched placebo for 26 weeks. The highest cagrilintide dose (4.5 mg) produced a mean 10.8% body-weight reduction versus 3.0% on placebo and 9.0% on liraglutide 3.0 mg — a result consistent with an amylin-receptor agonist that operates through partially overlapping but mechanistically distinct satiety pathways from the GLP-1 class.

The combination-therapy case ran in parallel. The Phase 2 trial in type 2 diabetes — Frias et al., Lancet 2023, 402(10403):720–730 — randomized 92 adults with type 2 diabetes and BMI ≥27 kg/m² on metformin (with or without an SGLT2 inhibitor) at 17 US sites to once-weekly CagriSema, semaglutide 2.4 mg, or cagrilintide 2.4 mg for 32 weeks. The combination produced a 15.6% body-weight reduction versus 5.1% on semaglutide alone and 8.1% on cagrilintide alone, and an HbA1c reduction of 2.2 percentage points versus 1.8 on semaglutide alone — directionally consistent with additive weight and additive-to-roughly-equivalent glycemic effects. The trial was small (~30 participants per arm) and the diabetic-cohort interpretation does not transfer mechanically to obesity without diabetes, but it set the framing under which the Phase 3 REDEFINE program was designed.

REDEFINE-1 is the trial that defines the molecule's clinical and commercial future, and the trial whose interpretation is genuinely contested. Garvey et al., N Engl J Med 2025 randomized 3,417 adults without type 2 diabetes and with BMI ≥30 kg/m² (or ≥27 with at least one obesity-related complication) in a 7:1:1:2.5 ratio to once-weekly CagriSema (n=2,108), semaglutide 2.4 mg (n=302), cagrilintide 2.4 mg (n=302), or placebo (n=705) for 68 weeks. Under the trial-product estimand — which estimates the effect if all participants adhered to treatment — mean weight loss was −22.7% on CagriSema, −16.1% on semaglutide alone, −11.8% on cagrilintide alone, and −2.3% on placebo. Under the treatment-policy estimand — which captures the intention-to-treat effect regardless of adherence — the comparable figures were −20.4% on CagriSema and −3.0% on placebo. Among CagriSema participants who adhered to therapy, 97.6% reached ≥5% loss, 60.2% reached ≥20%, 40.4% reached ≥25%, and 23.1% reached ≥30%. By any neutral metric this is a strong result, the largest weight-loss number published outside the retatrutide Phase 2 envelope.

The contested element is the magnitude of the incremental benefit of cagrilintide on top of high-dose semaglutide. The CagriSema-versus-semaglutide-alone gap under the trial-product estimand is 6.6 percentage points (22.7 vs 16.1) — meaningful but smaller than the implicit Novo Nordisk forecast that produced the publicly stated 25% target. When the December 2024 topline read out below that target, the stock fell roughly 20–26% in two trading sessions and at least seven analysts cut price targets. The trial's flexible-dose-titration design — which allowed dose reduction for tolerability — meant only 57.3% of CagriSema participants were on the full target dose at week 68, which Novo cited in explaining the gap between the trial-product and treatment-policy estimands. Reasonable observers read the result two ways: as confirmation that amylin agonism adds clinically meaningful loss to GLP-1 monotherapy, or as confirmation that the combination's edge over semaglutide alone is narrower than the tirzepatide Phase 3 envelope already on the market. Both readings are compatible with the data. The GLP-1 receptor pharmacology dossier and the fat-loss decision guide address how an editor on this site would frame the head-to-head positioning question.

REDEFINE-2 — the Phase 3 trial in adults with type 2 diabetes — was published in parallel (NEJM 2025). 1,206 participants were randomized 3:1 to CagriSema (n=904) or placebo (n=302) for 68 weeks; mean body-weight change was −13.7% on CagriSema versus −3.4% on placebo, and 73.5% of CagriSema participants reached HbA1c ≤6.5% versus 15.9% on placebo. The weight-loss magnitude in the diabetic cohort is smaller than in REDEFINE-1, which has been the consistent pattern for incretin and incretin-combination therapy across SURPASS, SURMOUNT, and STEP — diabetic patients lose less weight on the same drug than non-diabetic patients with obesity, and CagriSema is no exception.

Practical access in 2026 is a separate question from the trial program. As of this entry's last review, cagrilintide is not available as an approved monotherapy product anywhere; Novo Nordisk filed the CagriSema NDA with the FDA in mid-2025 and approval is pending. Compounded products labeled "cagrilintide" or "CagriSema" circulate in the gray-market research-chemical and compounding-pharmacy ecosystems, but the actual molecule's structural complexity (a 37-residue peptide with a C20 fatty-diacid conjugation, the same manufacturing-difficulty class as semaglutide and tirzepatide) makes meaningful-purity compounded supply outside the Novo Nordisk manufacturing chain implausible. The site declines to grade specific suppliers; the structural pharmacology argument applies regardless.